Rare Disease Report
Patients & Caregivers


In the United States, every year over 2,000 children and teenagers are treated with cisplatin. It's been well known that it causes hearing loss in a proportion of patients.
The FDA has granted Bayer's copanlisib a Priority Review designation for its New Drug Application (NDA) to treat relapsed or refractory follicular lymphoma patients
Less than 2 weeks after getting FDA approval for a rare form of lung cancer, Alunbrig (brigatinib) is now available via Biologics, a special oncology pharmacy division of McKesson Specialty Health.
In the past, getting children to stay still for radiation therapy often required general anesthesia. Not anymore Letting them watch Spongebob or Cars could be all it takes.
Platelet Disorders Support Association (PDSA) provides information for both clinicians and patients to better manage immune thrombocytopenia (ITP).
Dr Anthony Herbert talks about palliative care specialists in urban areas provide education to health professionals in non-urban areas about palliative care.
James Bussel, MD talks about immune thrombocytopenia (ITP) in children, its treatment and some of the data presented at ASPHO's 20th Annual Meeting in Montreal.
Communication is fundamental for delivering medical care. Not all health professionals are properly trained to converse about pediatric palliative care.
Clinical trial shows that the administration of sodium thiosulfate (STS) in pediatric cancer patients receiving cisplatin reduced developing hearing loss.
Valeria Smith M.D. of Baylor College of Medicine Pediatrics provides a retrospective chart review about where pediatric cancer patients die.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.